Latest Affinity Asset Advisors, LLC Stock Portfolio

Affinity Asset Advisors, LLC Performance:

2025 Q4: 24.64%YTD: 46.96%2024: 9.87%

Performance for 2025 Q4 is 24.64%, and YTD is 46.96%, and 2024 is 9.87%.

About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings

Affinity Asset Advisors, LLC is a hedge fund based in New York, NY. On 2026-02-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $1.8 Billions as of 31 Dec, 2025.

The top stock holdings of Affinity Asset Advisors, LLC are , INSM, . The fund has invested 5.3% of it's portfolio in APOGEE THERAPEUTICS INC and 4.5% of portfolio in INSMED INC.

The fund managers got completely rid off VERONA PHARMA PLC (VRNA), SPDR S&P 500 ETF TR (SPY) and MERUS N V (MRUS) stocks. They significantly reduced their stock positions in PERCEPTIVE CAP SOLUTIONS COR, UNIQURE NV (QURE) and MADRIGAL PHARMACEUTICALS INC (MDGL). Affinity Asset Advisors, LLC opened new stock positions in PRAXIS PRECISION MEDICINES I (PRAX), FORTE BIOSCIENCES INC (FBRX) and TERNS PHARMACEUTICALS INC (TERN). The fund showed a lot of confidence in some stocks as they added substantially to JADE BIOSCIENCES INC (AVTE), ENGENE HOLDINGS INC and CULLINAN THERAPEUTICS INC (CGEM).

Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Affinity Asset Advisors, LLC made a return of 24.64% in the last quarter. In trailing 12 months, it's portfolio return was 46.96%.

Performance
S&P 500

New Buys

Ticker	$ Bought
praxis precision medicines i	54,526,900
forte biosciences inc	26,983,400
terns pharmaceuticals inc	22,220,000
anaptysbio inc	21,558,700
cogent biosciences inc	12,432,000
tango therapeutics inc	8,860,000
sutro biopharma inc	8,658,780
arcus biosciences inc	7,149,000

New stocks bought by Affinity Asset Advisors, LLC

Additions

Ticker	% Inc.
jade biosciences inc	994
engene holdings inc	735
cullinan therapeutics inc	632
bridgebio pharma inc	392
sagimet biosciences inc	228
ovid therapeutics inc	169
cytokinetics inc	128
roivant sciences ltd	112

Additions to existing portfolio by Affinity Asset Advisors, LLC

Reductions

Ticker	% Reduced
perceptive cap solutions cor	-85.71
uniqure nv	-83.33
madrigal pharmaceuticals inc	-72.93
dianthus therapeutics inc	-56.12
centessa pharmaceuticals plc	-45.76
travere therapeutics inc	-40.00
establishment labs hldgs inc	-35.48
immunovant inc	-33.33

Affinity Asset Advisors, LLC reduced stake in above stock

Sold off

Ticker	$ Sold
karyopharm therapeutics inc	-12,456,200
akebia therapeutics inc	-6,688,500
autolus therapeutics plc	-2,852,500
milestone pharmaceuticals in	-1,333,330
verona pharma plc	-66,693,800
context therapeutics inc	-390,090
enliven therapeutics inc	-8,188,000
astria therapeutics inc	-2,184,000

Affinity Asset Advisors, LLC got rid off the above stocks

Sector Distribution

Affinity Asset Advisors, LLC has about 75.8% of it's holdings in Healthcare sector.

Sector	%
Healthcare	75.8
Others	24.2

Market Cap. Distribution

Affinity Asset Advisors, LLC has about 16.2% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	36.7
UNALLOCATED	24.2
SMALL-CAP	18.2
LARGE-CAP	16.2
MICRO-CAP	4.3

Stocks belong to which Index?

About 49.4% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.

Index	%
Others	50.4
RUSSELL 2000	49.4

Top 5 Winners (%)		%
VTYX	ventyx biosciences inc	111.0 %
NXTC	nextcure inc	108.9 %
NRIX	nurix therapeutics inc	105.3 %
WVE	wave life sciences ltd	102.5 %
ELYM	climb bio inc	99.0 %

Top 5 Winners ($)		$
	apogee therapeutics inc	43.0 M
VTYX	ventyx biosciences inc	30.8 M
WVE	wave life sciences ltd	23.2 M
AGLE	spyre therapeutics inc	22.8 M
	abivax sa	21.6 M

Top 5 Losers (%)		%
RZLT	rezolute inc	-73.8 %
	adagio med hldgs inc	-46.4 %
RCKT	rocket pharmaceuticals inc	-39.1 %
QURE	uniqure nv	-34.4 %
ACLX	arcellx inc	-20.2 %

Top 5 Losers ($)		$
RZLT	rezolute inc	-15.7 M
ACLX	arcellx inc	-8.7 M
QURE	uniqure nv	-6.0 M
ALKS	alkermes plc	-2.3 M
	mineralys therapeutics inc	-1.2 M

Affinity Asset Advisors, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Affinity Asset Advisors, LLC

Affinity Asset Advisors, LLC has 82 stocks in it's portfolio. About 34% of the portfolio is in top 10 stocks. RZLT proved to be the most loss making stock for the portfolio. was the most profitable stock for Affinity Asset Advisors, LLC last quarter.

Last Reported on: 13 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ACLX	arcellx inc	1.95	523,725	34,146,900	added	4.74

AGLE	spyre therapeutics inc	2.67	1,432,590	46,931,700	added	0.94

AKBA	akebia therapeutics inc	0.00	0.00	0.00	sold off	-100

ALKS	alkermes plc	1.59	1,000,000	27,980,000	reduced	-20.00

AMGN	amgen inc	0.19	10,000	3,273,100	new

ANAB	anaptysbio inc	1.23	444,692	21,558,700	new

ARWR	arrowhead pharmaceuticals in	0.26	70,000	4,647,300	new

ASND	ascendis pharma a/s	0.36	30,000	6,397,200	new

ATXS	astria therapeutics inc	0.00	0.00	0.00	sold off	-100

AUTL	autolus therapeutics plc	0.00	0.00	0.00	sold off	-100

AVTE	jade biosciences inc	0.63	714,956	11,031,800	added	994

AVTX	avalo therapeutics inc	1.09	1,051,050	19,087,100	added	4.46

BBIO	bridgebio pharma inc	1.40	320,000	24,476,800	added	392

BLTE	belite bio inc	0.18	20,000	3,199,200	new

CELC	celcuity inc	0.37	3,000,000	6,515,700	unchanged	0.00

CGEM	cullinan therapeutics inc	1.14	1,932,110	19,997,300	added	632

CLDX	celldex therapeutics inc new	0.54	350,000	9,506,000	added	16.67

CMPS	compass pathways plc	0.08	200,000	1,380,000	unchanged	0.00

CNTA	centessa pharmaceuticals plc	0.86	600,552	15,019,800	reduced	-45.76

CNTX	context therapeutics inc	0.00	0.00	0.00	sold off	-100